Commercial Launch of Fortacin™ a Breakthrough Treatment for Premature Ejaculation Now Available in the UK and, from 2017, in Continental Europe

Regent Pacific Announces 2016 Interim Financial Results Substantial Increase in Profits and Shareholder Equity

Regent Pacific Secures Variation Approval for Commercial Launch of the Reduced Dose Can Version of its Premature Ejaculation Treatment PSD502®

Regent Pacific further invests up to GBP 3 million in The Diabetic Boot Company Limited, increasing its stake initially to 23.0% and potentially up to 33.1%

Regent Pacific’s Premature Ejaculation Treatment PSD502® Enters Final Stage of Commercialisation

Regent Pacific Announces Successful Acquisition of London AIM listed Plethora Solutions Holdings Plc Transition into a Hong Kong Listed Healthcare Investment Vehicle